Clinical Trial of Losmapimod(FSGS)

A Study to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)

Study overview

The purpose of this study is to measure the safety and effectiveness of the medicine losmapimod in treating patients with idiopathic focal segmental glomerularsclerosis (FSGS). Patients who take part in the study will be asked to take losmapimod by mouth two times a day for approximately 6 months under close physician supervision. The goal is to achieve either partial or complete remission of proteinuria. You will continue to be followed for approximately 9 months after beginning study medication.

Eligibility Criteria

You MIGHT be eligible to participate if you:

  • Are between the ages of 18 and 70
  • Have had a kidney biopsy confirming primary FSGS
  • Are spilling 2 or more grams of protein in your urine
  • Are willing to have additional lab tests completed to confirm eligibility

    You CANNOT participate if you:

  • Have Type 1 or 2 diabetes mellitus or other condition that caused your FSGS
  • Have had an organ transplant
  • Have congestive heart failure

    how to get involved

    For more information or to participate, please contact:

    Hailey Desmond, MS, CCRP
    Phone: (734) 232-4851 or toll-free 1-844-618-2479
    Email: umkidneystudies@umich.edu

    Sponsor: GlaxoSmithKline

    Currently Enrolling Sites

  • Univ of North Carolina (Dr. Nachman, contact information pending)
  • Stanford Univ (Dr. Lafayette, contact information pending)
  • Ohio State Univ (Dr. Rovin, contact information pending)
  • MetroHealth System (Dr. Sedor, contact information pending)
  • UCLA (Dr. Rastogi, contact information pending)
  • Univ of Michigan (Dr. Gipson, contact information pending)
  • Temple Univ (Dr. Johnstone, contact information pending)
  • Univ of Alberta (Dr. McMahon, contact information pending)
  • Univ of British Columbia (Dr. Barbour, contact information pending)
  • Univ Health Network (Dr. Hladunewich, contact information pending)